Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Mega cap

Divi's Laboratories boosts dividend to ₹30 after FY26 profit climb

The pharmaceutical major recorded an annual net profit of ₹2,568 crore, prompting the board to double the final dividend payout.


Mkt cap₹1.83 lakh cr
P/E71.19×
ROE14.64%
Debt / eq.0.00
Div yld0.44%
₹30 / share Final dividend recommended by the board, up from ₹15 last year.

What's new

  • Annual revenue grew 13.9% to ₹11,067 crore for FY26.
  • Net profit rose 17.2% to ₹2,568 crore.
  • Q4 revenue increased 11.8% to ₹2,986 crore, aided by a ₹90 crore foreign exchange gain.

Why this matters

The decision to double the dividend despite steady growth suggests management is comfortable with current cash levels. For a large-cap firm, this return of capital is the primary takeaway from an otherwise predictable set of annual figures.

What we're watching

  • Free cash flow sustainability following the higher payout.
  • Shareholder sentiment at the annual general meeting on August 10.
  • Currency volatility impact on future quarterly margins.

The full read

Divi's Laboratories closed FY26 with a 13.9% lift in revenue to ₹11,067 crore and a 17.2% gain in net profit to ₹2,568 crore. While the headline performance tracks with steady pharmaceutical sector growth, the board's decision to raise the final dividend to ₹30 per share—up from ₹15 last year—is the actionable news. Fourth-quarter revenue reached ₹2,986 crore, an 11.8% increase. This result includes a notable ₹90 crore foreign exchange gain, which is roughly nine times the amount recorded in comparable periods. By lifting the dividend payout, management signals comfort with free cash flow, prioritizing shareholder returns after a strong fiscal year. The numbers are broadly in line with expectations, confirming a steady finish. The next test for shareholders is the annual general meeting on August 10.

Questions answered

How did the dividend payout change compared to last year?
The board recommended a final dividend of ₹30 per share for FY26, exactly double the ₹15 per share paid out the previous year.
What drove the company's revenue growth in the final quarter?
Divi's Laboratories reported Q4 revenue of ₹2,986 crore, an increase of 11.8% year-on-year. A significant portion of this growth was bolstered by a nine-fold increase in foreign exchange gains, which reached ₹90 crore.
What was the total annual performance for FY26?
The company reported consolidated annual revenue of ₹11,067 crore and a net profit of ₹2,568 crore. These figures represent year-on-year growth of 13.9% and 17.2%, respectively.
When is the annual general meeting scheduled?
The company has set its annual general meeting for August 10.
Mentioned: Divi's Laboratories Ltd. · August 10 AGM
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.